Home › Compound Library › KPV
Immune modulation
KPV: The Three-Amino-Acid Anti-Inflammatory, and What the Research Shows
The short answer
KPV is the smallest compound in our library: three amino acids, cut from the tail end of alpha-MSH, a hormone your own body makes. It appears to damp inflammation by acting on NF-kB, the master switch for inflammatory genes. The research is mostly in mice, especially gut inflammation, and it is not FDA approved.
Questions people ask about KPV
KPV at a glance
| Also called | Lysine-Proline-Valine; alpha-MSH (11-13) |
|---|---|
| What it is | Tripeptide fragment of the hormone alpha-melanocyte-stimulating hormone |
| Acts on | NF-kB signalling; taken into gut cells by the PepT1 transporter |
| Main system | Immune regulation: gut, skin, general inflammation |
| Evidence level | Animal and cell studies; human trials not yet run |
| FDA status (Sept 2026) | Not approved. In July 2026 an FDA advisory committee recommended it for the list of substances pharmacies may compound |
| In sport | Not named on the WADA prohibited list as of 2026 |
What is KPV?
Alpha-MSH is a hormone best known for skin pigmentation, but it is also one of the body’s own anti-inflammatory signals. KPV is its last three amino acids, and it turns out that most of the anti-inflammatory activity survives in that fragment (reference 2).
Being tiny has practical consequences. It is cheap to make, stable enough to survive some routes that destroy larger peptides, and small enough to be carried into cells by a transporter meant for food-derived peptides.
Regenerative Resilience (pp. 127–128) places it among the immune-modulating compounds, and Targeted Peptide Systems profiles it at pp. 136–138.
How does KPV work?
The target is NF-kB, a protein that acts as the on-switch for a large set of inflammatory genes. When NF-kB is activated, cells produce inflammatory messengers such as TNF-alpha, IL-6 and IL-1beta. KPV interferes with that activation, so fewer of those messengers get made.
Regenerative Resilience (p. 128) describes the consequence in protocol terms: it reduces the inflammatory drive without broadly suppressing immune function, which is the difference between damping a signal and switching off a defence.
The gut is the special case. Intestinal cells carry a transporter called PepT1 that normally absorbs small peptides from digested food. KPV is small enough to ride it, which gives it direct access to the cells lining an inflamed gut (reference 1).
What does the research show?
The key study. Dalmasso and colleagues, 2008, in Gastroenterology: in mouse models of colitis, KPV taken up through PepT1 reduced intestinal inflammation, and it worked at very low concentrations (reference 1).
The background. A 2008 review in Endocrine Reviews covers alpha-MSH and its tripeptides, setting out the anti-inflammatory and protective effects documented across tissues (reference 2). This is the paper Regenerative Resilience cites at p. 350.
Where the evidence stands. No human trial of KPV has been completed, for gut disease, skin conditions or anything else, so everything above is animal and cell work. Clinicians working with it do report benefit, and that experience counts for something; it is how most promising compounds first get noticed. It is not the same as trial data, and the mouse colitis result is best read as a signal strong enough to justify testing in people.
The delivery research has gone further than the treatment research. A 2017 study in the Journal of Pharmaceutical Sciences measured KPV crossing samples of human skin, helped through by iontophoresis and microneedles (reference 6). That is part of why topical and oral routes are discussed at all for a peptide this small. It tells us KPV can get where it needs to go; what it does once it arrives, in a person rather than a mouse, is the part still to be tested.
Side effects and cautions
KPV has not been through human safety trials, so what follows comes from the molecule rather than from clinical data, and several things about the molecule point in its favour. It is a fragment of a hormone the body already makes. The quantities involved are very small. Animal studies have not turned up notable toxicity, even at generous exposures.
That is a good starting position rather than a finished safety record. The open risks are mostly about the product rather than the peptide: purity, contamination, and no manufacturer answerable for what is in the vial, which is what third-party testing exists to cover.
Inflammatory bowel disease, autoimmune conditions and chronic skin disease all have treatments with strong evidence behind them. If you have one of those diagnoses, the sensible order is to keep what is working and raise KPV with your clinician as a possible addition rather than a replacement. That is a sequencing question, not a reason to dismiss it.
Is KPV legal or FDA approved?
Not FDA approved. On 23 July 2026, the FDA’s Pharmacy Compounding Advisory Committee voted to recommend KPV for the 503A bulks list, one of six peptides it recommended that day (references 3, 4). That vote is a recommendation. It is not binding, and formal rulemaking has to follow before compounding pharmacies can use it.
Sport: KPV is not named on the 2026 WADA prohibited list. Athletes should still check with their own governing body, since lists are updated annually and substances can be covered by broader categories.
This page is reviewed and updated as the status changes.
KPV vs BPC-157 and the other immune peptides
The compounds people compare KPV with are doing different jobs, and Regenerative Resilience (p. 76) sets out the distinction that matters: match the compound to the failure you have actually identified.
- vs BPC-157: BPC-157 is a repair compound, working largely through new blood vessel growth; KPV is an anti-inflammatory, working on a signalling switch. They are often discussed together for gut problems because the gut usually needs both. See our BPC-157 profile.
- vs thymosin alpha-1: thymosin alpha-1 works further upstream, restoring immune regulation through T cells. It is an approved medicine in more than thirty countries and, in the US, holds FDA orphan drug designation for four conditions, which is recognition that the science is taken seriously rather than clearance to sell it here. KPV works more narrowly, damping one signalling pathway.
- vs LL-37 and VIP: different mechanisms again, suited to barrier defence and to combined immune and blood flow problems respectively.
- vs steroids: corticosteroids are the heavyweights here, broadly immunosuppressive with decades of evidence behind them, and carrying the side-effect burden that comes with that reach. KPV is aiming at something more precise, damping one signalling pathway instead of suppressing the whole response. Its evidence base is younger, which is the trade-off rather than a verdict.
Our journal article on the immune rules most protocols ignore covers how the book decides between them.
Risk, benefit, and the conversation this page is for
Thin evidence is not the same as evidence of harm. Those two get collapsed into one idea constantly, and they are different findings. For kpv, what exists is a quiet safety record next to an unfinished efficacy record: the toxicology that has been done has not turned up notable harm, and the trials that would show how well it works have not been run. On current evidence the realistic downside is that it does less than people hope, not that it does damage. Each compound still has its own cautions, and the safety section above is where ours are.
The regulatory picture is moving, and it is moving one compound at a time. In July 2026 an FDA advisory committee recommended six peptides, BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, for the list of bulk substances compounding pharmacies may use. The same committee has turned peptides down and still does: ipamorelin and CJC-1295 sit in Category 2, barred from compounding. The distinction is the useful part. Each compound is being read on its own risk record rather than lumped under one verdict called unapproved.
The clinicians working with these compounds are not fringe, and their reasoning is comparative rather than enthusiastic. The approved options for chronic inflammation and slow-healing tissue carry burdens that are thoroughly documented: long-term anti-inflammatories on the gut and kidneys, repeated corticosteroid injections on connective tissue, glucose control and bone. Weighed against that, a compound with a quiet toxicology record and an incomplete efficacy record is a reasonable thing to discuss. It is not a reasonable thing to promise, and that is the line this page tries to hold.
Which is the point of the series. Nothing here is a recommendation to use kpv. People misuse approved medicines and unapproved compounds alike, and that is neither the purpose nor the intent of this page. The point is a better conversation than the internet usually allows: with a clinician who knows your history, your labs and everything else you take, and who can help build a plan that fits you.
KPV: frequently asked questions
What is KPV peptide?
A three-amino-acid fragment of alpha-MSH, a hormone the body produces. It is studied as an anti-inflammatory that acts on NF-kB signalling.
What are KPV’s benefits?
In animal research, reduced intestinal inflammation (reference 1) and the broader anti-inflammatory effects documented for alpha-MSH fragments (reference 2). Those results come from animal work; the human version of the question has not been trialled yet.
Is KPV good for leaky gut?
It is one of the two compounds most discussed for gut inflammation, along with BPC-157, and the gut is where its strongest animal evidence sits. Our article on leaky gut and the peptides studied for it goes through the mechanism. Gut symptoms deserve a medical assessment first, since conditions like coeliac disease and IBD need specific treatment.
Does KPV work orally?
Its size and the PepT1 transporter are the reason oral and topical routes are discussed at all, where most peptides would be destroyed by digestion (reference 1). That work is in animals.
What are KPV’s side effects?
What is known is favourable as far as it goes: animal studies have not flagged notable toxicity, and the molecule is a fragment of one the body already makes. A catalogued human side-effect list does not exist yet. The open risks are mostly product quality, meaning purity and contamination.
Is KPV FDA approved?
No. In July 2026 an FDA advisory committee recommended adding it to the list of substances compounding pharmacies may use, which is a non-binding step and not an approval (references 3, 4).
Is KPV banned in sport?
It is not named on the 2026 WADA prohibited list. Check with your sport’s governing body, as lists change each year.
KPV vs BPC-157: which one?
They do different things. BPC-157 supports repair; KPV damps inflammation. Regenerative Resilience (pp. 74–76) argues that assessing the immune environment comes before choosing a repair compound at all.
Where KPV appears in our books
This page is the plain-language overview. The books go further: mechanism detail, evidence tiers, how KPV fits a full protocol, and the cautions that go with it. Page numbers refer to the print editions.
Books marked Look Inside include these exact pages in their free preview.
Related compounds
See how KPV fits a protocol
The free Protocol Builder maps the pathways a compound works on and shows what complements it for your goal, built from the same database as this library.
Open the Protocol BuilderSee the book seriesReferences
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. View source
- Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581–602. View sourceCited in Regenerative Resilience (p. 350)
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. View source
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
- World Anti-Doping Agency. The 2026 Prohibited List. View source
- Pawar K, Kolli CS, Rangari VK, Babu RJ. Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. J Pharm Sci. 2017;106(7):1814–1820. View sourceHuman skin samples in the laboratory, not a clinical trial
How this page is maintained. Regulatory status and trial results change. We review this page against current sources and update it as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. KPV is discussed here for education. Nothing on this page is a recommendation to use it or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.